Merck & Co Inc MRK has surpassed expectations with fourth-quarter revenue and adjusted earnings, largely driven by its blockbuster cancer drug Keytruda and HPV prevention vaccine, Gardasil. While the company recorded a net quarterly loss due to charges related to a deal with Daiichi Sankyo, Merck’s patent for Keytruda is set to expire in 2028, prompting the need for additional products. Similar to its peers Moderna Inc. and Pfizer Inc., the company is turning its focus to oncology to drive future revenue.
Mainz Biomed N.V. has also made significant strides in the field, with impressive results from its colorectal cancer screening solution ColoAlert®, backed by successful European and U.S. studies. The company has further cemented its commitment to oncology with the launch of a new European Oncology Lab, marking a major expansion in its capabilities.
Merck and Moderna have made waves with midstage trial results demonstrate impressive potential for the combined treatment of Keytruda and an experimental mRNA cancer vaccine in reducing the risk of recurrence or death of melanoma. These results, which have been sustained over time, have paved the way for a confirmatory late-stage trial. Additionally, the two companies have initiated a trial to assess the combination’s efficacy in combatting lung cancer, marking a significant step forward in the battle against these life-threatening diseases.
Mainz Biomed has also revolutionized colorectal cancer screening, leveraging advanced PCR technology to enable earlier detection with greater accuracy. The company’s non-invasive and highly sensitive screening method has demonstrated promising results, with high sensitivity and specificity for colorectal cancer and advanced adenoma. Moreover, the establishment of the European Oncology Lab promises to expand access to colorectal cancer screening, benefiting millions of individuals and presenting a new revenue opportunity for the company.
These advancements represent a significant leap forward in cancer diagnostics and treatment, setting the stage for a transformative year in combating one of the world’s biggest health battles.
DISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.
This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.
